Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial

Autores da FMUP
Participantes de fora da FMUP
- Protic, Marijana
- De Hertogh, Gert
- Chan, Lai Shan
- Pollack, Paul
- Jairath, Vipul
- Carlier, Hilde
- Hon, Emily
- Feagan, Brian G.
- Harpaz, Noam
- Pai, Rish
- Reinisch, Walter
Unidades de investigação
Abstract
BACKGROUND & AIMS: Histologic evaluation of mucosal healing in Crohn's ` s disease is an evolving treatment target. We evaluated histologic outcomes for mirikizumab efficacy fi cacy and associations with endoscopic and 1-year outcomes. METHODS: Biopsy specimens from 1 ileal and 4 colonic segments were evaluated at weeks 0, 12, and 52 from each of the 170 SERENITY participants. Criteria for the weeks 12 and 52 histologic response were no epithelial neutrophils or epithelial damage, or > 50% decrease in either the Robarts Histopathology Index or the active Global Histologic Disease Activity Score, and remission (no mucosal neutrophils and no epithelial damage) had to be met in all biopsy specimens. Agreement was evaluated between histologic and endoscopic end points. Associations between 1-year outcomes and week 12 histologic and endoscopic response were evaluated.<br /> RESULTS: At week 12, 1000 mg mirikizumab resulted in greater rates of histologic response (66% vs 27%; P < .001) and remission (26% vs 6%; P < .01) than placebo. Rates were numerically similar at 1 year (mirikizumab pooled response, 46%-69%; - 69%; remission, 13%-31%). - 31%). Agreement between week 12 histologic and endoscopic response was 69% (Cohen's ` s kappa coefficient fi cient [K] K ] = 0.40) and remission was 83% (K K = 0.38) in all pooled arms, including placebo. At 1 year, the percentage of participants who received any dose of mirikizumab and achieved endoscopic remission differed by their week 12 response: histologic (20%), endoscopic (25%), combined histology-endoscopy (45%), or neither (4%) (P P = .003). CONCLUSIONS: In a post hoc analysis of phase 2 data, mirikizumab induced and sustained histologic response and remission in Crohn's ` s disease over 52 weeks. Early combined histologic-endoscopic - endoscopic response was associated with endoscopic remission after 1 year of treatment with mirikizumab
Dados da publicação
- ISSN/ISSNe:
- 1542-7714, 1542-3565
- Tipo:
- Article
- Páginas:
- 1878-188810
- Link para outro recurso:
- www.scopus.com
Clinical Gastroenterology and Hepatology W.B. Saunders Ltd
Citações Recebidas na Web of Science: 4
Citações Recebidas na Scopus: 5
Documentos
- Não há documentos
Filiações
Keywords
- Crohn's ` s Disease; Histology; Mucosal Healing; Endoscopy
Proyectos asociados
Gut microbiome and IBD therapy: an interplay?
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (GutIBD) . 2021
Iron deficiency and inflammatory bowel disease. Correlation with inflammation and Vitamin D status.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (IronIBD) . 2021
Looking 4WARD: The role of dipeptidyl peptidase 4 (DPP-4) in inflammatory bowel disease (IBD) as a novel biomarker for predicting disease activity and monitoring response to therapy in IBD patients.
Investigador Principal: Fernando José Magro Dias
Estudo Observacional Académico (4WARD) . 2021
Isolated Ulceration of Crohn’s Anastomosis
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After Biopsy
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2022
Burden of Inflammatory Bowel Disease in Portugal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico (Inflammatory Bowel) . 2023
Therapeutic Drug Monitoring: An Emergent Approach in Inflammatory Bowel Disease
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2021
Contributo da endoscopia, biomarcadores e imagiologia na evolução clinica dos doentes com doença inflamatória intestinal
Investigador Principal: Fernando José Magro Dias
Estudo Clínico Académico . 2019
Citar a publicação
Magro F,Protic M,De Hertogh G,Chan LS,Pollack P,Jairath V,Carlier H,Hon E,Feagan BG,Harpaz N,Pai R,Reinisch W. Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 Trial. Clin. Gastroenterol. Hepatol. 2024. 22. (9):p. 1878-188810. IF:12,600. (1).